|
Market Closed -
Japan Exchange
10:30:00 02/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 7,107.00 JPY | +1.69% |
|
+3.22% | +30.93% |
| 09-25 | Kobayashi Pharmaceutical Says No Decision Made on Potential Take-Private Deal by NSSK, CVC Capital Partners | MT |
| 09-24 | Kobayashi Reportedly in ¥500 Billion Buyout Talks After Red-Yeast Case | CI |
Company Valuation: Kobayashi Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 704,427 | 650,295 | 503,841 | 463,131 | 403,511 | 528,325 | - | - |
| Change | - | -7.68% | -22.52% | -8.08% | -12.87% | 30.93% | - | - |
| Enterprise Value (EV) 1 | 596,011 | 546,554 | 424,992 | 398,232 | 333,575 | 465,912 | 457,731 | 448,701 |
| Change | - | -8.3% | -22.24% | -6.3% | -16.24% | 39.67% | -1.76% | -1.97% |
| P/E | 35.8x | 34.8x | 25.3x | 46x | 110x | 50.7x | 39.2x | 31.8x |
| PBR | 3.59x | 3.47x | 2.47x | 2.18x | 1.92x | 2.52x | 2.43x | 2.35x |
| PEG | - | 12.08x | 7.7x | -0.9x | -1.7x | 0x | 1.3x | 1.4x |
| Capitalization / Revenue | 4.54x | 3.91x | 2.9x | 2.8x | 2.43x | 3.08x | 2.95x | 2.83x |
| EV / Revenue | 3.84x | 3.29x | 2.45x | 2.4x | 2.01x | 2.71x | 2.55x | 2.41x |
| EV / EBITDA | 19.3x | 17.1x | 13.3x | 12.1x | 14.1x | 21.1x | 16.8x | 14.4x |
| EV / EBIT | 22.9x | 20.5x | 16.5x | 16x | 22.4x | 36.6x | 26.2x | 20.9x |
| EV / FCF | 31.8x | 31.1x | -350x | -29.2x | 68.5x | 32.4x | 30.1x | 26.2x |
| FCF Yield | 3.15% | 3.22% | -0.29% | -3.42% | 1.46% | 3.09% | 3.33% | 3.81% |
| Dividend per Share 2 | 83 | 90 | 101 | 102 | 104 | 106 | 109.5 | 114.3 |
| Rate of return | 0.92% | 1% | 1.49% | 1.64% | 1.92% | 1.49% | 1.54% | 1.61% |
| EPS 2 | 252.4 | 259.6 | 268.2 | 135.4 | 49.19 | 140.1 | 181.4 | 223.7 |
| Distribution rate | 32.9% | 34.7% | 37.7% | 75.3% | 211% | 75.6% | 60.4% | 51.1% |
| Net sales 1 | 155,252 | 166,258 | 173,455 | 165,600 | 165,742 | 171,748 | 179,252 | 186,553 |
| EBITDA 1 | 30,900 | 32,027 | 31,837 | 32,800 | 23,600 | 22,065 | 27,283 | 31,225 |
| EBIT 1 | 26,065 | 26,669 | 25,780 | 24,860 | 14,923 | 12,743 | 17,443 | 21,425 |
| Net income 1 | 19,715 | 20,022 | 20,338 | 10,067 | 3,656 | 10,524 | 13,655 | 16,488 |
| Net Debt 1 | -108,416 | -103,741 | -78,849 | -64,899 | -69,936 | -62,413 | -70,594 | -79,623 |
| Reference price 2 | 9,040.00 | 9,030.00 | 6,790.00 | 6,230.00 | 5,428.00 | 7,107.00 | 7,107.00 | 7,107.00 |
| Nbr of stocks (in thousands) | 77,923 | 72,015 | 74,203 | 74,339 | 74,339 | 74,339 | - | - |
| Announcement Date | 04/02/22 | 14/02/23 | 09/02/24 | 10/02/25 | 10/02/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 50.71x | 2.71x | 21.12x | 1.49% | 3.35B | |
| 21.29x | 4.07x | 14.88x | 3.03% | 337B | |
| 28.62x | 4.4x | 18.16x | 2.08% | 223B | |
| 17.73x | 2.66x | 11.72x | 3.6% | 128B | |
| 23.18x | 3.45x | 14.51x | 2.52% | 67.17B | |
| 51.2x | 7.23x | 27.86x | 0.31% | 45.15B | |
| 38.12x | 6.13x | 26.61x | 2.45% | 44.87B | |
| 18.12x | 2.57x | 10.73x | 4.91% | 33.04B | |
| 31.81x | 2.4x | 13.47x | 1.69% | 33.27B | |
| 14.14x | 2.31x | 10.68x | 5.47% | 31.38B | |
| Average | 29.49x | 3.79x | 16.97x | 2.75% | 94.59B | |
| Weighted average by Cap. | 25.03x | 3.99x | 16.07x | 2.78% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4967 Stock
- Valuation Kobayashi Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
